CRISPR Gene-Edited immune cells aim to fight lung cancer – but trial never started
NCT ID NCT05566223
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial planned to test a new approach for people with metastatic non-small cell lung cancer. Doctors would remove immune cells from the tumor, edit them with CRISPR to remove a gene called CISH, and then infuse them back to help fight the cancer. However, the trial was withdrawn before any patients were enrolled, so we have no data on safety or effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CISH-inactivated tumor-infiltrating lymphocytes (TILs) made with CRISPR gene editing
What this could lead to
If it works, this could point toward a new treatment option for advanced lung cancer that uses a patient's own immune cells.
What could go wrong
The trial was withdrawn before enrolling anyone, so no results exist. Gene-edited cell therapies are complex and may cause severe side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, 55455, United States